Obtenga las últimas noticias sobre las acciones de Evaxion con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de EVAX

Últimas noticias sobre

EVAXION A/S

Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Long Ideas

AREN

CSTM

GDYN

GEAR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: CSTM, VIRX, EVAX, AREN y GDYN.

5 acciones en el foco este viernes: CSTM, VIRX, EVAX, AREN y GDYN

Evaxion AS

Penny Stocks

Press Releases

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Biotech

General

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Opinion

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

EDAP

GTBP

RNXT

XNCR

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Celularity

CEL-SCI

Dyadic International, Inc. - Common Stock

Dyadic International

Equillium

Evaxion

FibroGen

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kezar Life Sciences

Lantern Pharma

LAVA Therapeutics

MAIA Biotechnology

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Plus Therapeutics

Serina Therapeutics

Skye Bioscience

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

Edward Jones

Lake Street

HC Wainwright & Co.

Ladenburg Thalmann

Oppenheimer

Comments

Evaxion Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL